Benzinga | Jul 27, 2021 11:13AM EDT

Bionano Genomics Reports Number Of Presentations On Optical Genome Mapping Between Aug. 1-4

Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a record number of optical genome mapping (OGM) presentations scheduled to appear at the annual Cancer Genomics Consortium (CGC) meeting being held from August 1 - 4, 2021. Across this four-day event, the meeting features 10 presentations by Bionano's Saphyr(r) customers highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics.

In 2020, more than 500 participants from around the globe attended the CGC's virtual meeting and attendance for this year's four-day event is anticipated to be even higher. The 10 upcoming presentations featuring Saphyr-generated OGM data are listed below along with the associated application areas:

OGMApplication Presenter Affiliation Presentation Title Area Dr. Miriam Children's Optical genome mapping reveals Bornhorst National novel structural variants in Solid Tumor Hospital pediatric high grade gliomas.Analysis Clinical utility and feasibility Dr. Nikhil Augusta of adopting optical genome Sahajpal University mapping for chromosomal characterization of solid tumors. MD Anderson Optical genome mapping for Dr. Rashmi Cancer chromosomal structural variants Kanagal-Shamanna Center analysis in hematological malignancies. Children's Complementarity of RNA sequencing Dr. Gordana Raca Hospital and optical genome mapping in Los Angeles detection of rare fusions in pediatric B-ALL. The Johns Adoption of optical genomeHematological Dr. Victoria Hopkins mapping in clinical cancer Malignancies Stinnett University cytogenetic laboratory: A stepwise approach. UT MD Optical Genome Mapping Reveals Dr. Guilin Tang Anderson Genomic Complexity and Detects Cancer Novel Genetic Abnormalities in Center T-Lymphoblastic Leukemia. City of Integrative cytogenomics studies Hope using optical genome mapping in Dr. Jia-Chi Wang National two cases with chronic Medical lymphocytic leukemia. Center Next-generation cytogenetics:Prenatal Nikhil Sahajpal Augusta Proposal for a cost-effective Genetics University approach for comprehensive testing of prenatal cases. Optical genome mapping and SNPProducts of Dr. Nikhil Augusta microarray: integrated workflow Conception Sahajpal University for optimizing analysis of products of conception.Postnatal/ University Genomic structural variations inConstitutional Dr. Thuy Phung of South lymphatic anomalies. Genetics Alabama

"We are thrilled to see the broad adoption of OGM by members of the CGC community of clinical researchers, who have rigorously compared the performance of OGM to the standard of care methods, such as, Karyotyping, FISH and other targeted tests," said Alka Chaubey, PhD, Chief Medical Officer of Bionano Genomics. "In all the presentations, there are recurring themes of increased sensitivity, higher success rates and an easier workflow using OGM for the detection of clinically relevant structural variations in prenatal, postnatal/constitutional genetics, blood cancers and solid tumor applications."

In addition, Dr. Alka Chaubey will be presenting at the CGC meeting on August 2nd and leading a panel discussion on how OGM has the potential to usher in a new era for cancer genomics.

"This year's CGC meeting has the greatest number of presentations featuring Bionano data to date," commented Erik Holmlin, PhD, CEO of Bionano Genomics. "We believe this multitude of presentations shows how significant Bionano's presence and that of OGM has become in the cancer research community. The progress we are seeing here within the US market, with all this OGM data being presented at the CGC meeting, is extremely encouraging and further reinforces our belief in the value proposition of our solution."

For more details and to register for this online event please go to https://cancergenomics.org/meetings/cgc_annual_meeting.php